The Biggest Thing Since the Internet

Having trouble viewing this issue? Click here. Refer a Friend to Wealth Daily.

The Biggest Thing Since the Internet By Steve Christ | Thursday, June 23rd, 2011 Long before the Internet became the "Information Superhighway," it was nothing more than an odd realm of scientists, academics, defense types and computer geeks. Of course, it wasn't long before scores of entrepreneurs and their venture capitalist friends recognized its profit potential and succeeded in turning it into one of the greatest investment opportunities of a lifetime. If you were there in the '90s, then you know exactly what I'm talking about. Advertisement How will you get to work when gas is $20 a gallon? How will you feed your family when a loaf of bread is $15? If you can't answer these questions... You should watch this video and find out. If you weren't, you ought to ask some of the people that were. I'm sure they will be happy to tell you about the fortunes they made back in the day investing in high-flying dot-com stocks. I mean, Cisco Systems (NASDAQ: CSCO) went from its 1990 IPO price of $0.08 per share to $80 by 2000 for a gain of over 99,000%. Now that's one for the investment hall of fame. But like all great and bubbly investment opportunities, even the Internet eventually ran its course. The next big thing Ever since then investors have been looking for the "next big thing" that will storm the markets the same way the Net did over fifteen years ago. So where is the next big thing lurking in today's markets?... From where I sit, it's within the biotech sector. That’s because ultimately I believe the biotech sector is on the cusp of revolutionizing the way we think about disease, cancer, disabilities and their eventual treatment options. And while these things have always been the stuff of our most hopeful dreams — to live without disease — I think what we're going see in the future will dwarf the progress our grandparents witnessed in their lifetimes. That’s why it has been so fascinating to cover the fast growing areas of DNA vaccines, regenerative medicine and stem cell research. What makes the sector so different from the Internet, though, is these advances are not going to be delivered to us overnight. If the Internet was the hare, the biotech sector is definitely the tortoise. That is just the nature of the beast and the aspect most investors seem to have the hardest time with. In this arena, there are simply no short cuts. As a result, the road for these types of companies is long, expensive and arduous. But I can tell you this: every time I sit down with the CEO of a biotech company, I realize they are all true believers in the roads they are traveling. You see, by and large these CEO's are quite different from the heads of firms in other industries. For biotech CEOs, it's more about the science behind saving lives. It’s also about meeting goals, producing desired results and pushing the ball closer and closer to the goal line. Without exception, these are really the smartest guys in the room, and I admire them for what they hope to one day accomplish. Talk about goals....all these folks want to do is cure cancer and put an end to disease. In short, they want nothing less than to completely turn the medical field on its head. The promise of stem cell research Take the promise that underlies the current goals inherent in stem cell research, for instance. Dr. Hans Keirstead, a renowned UC Irvine scientist, believes cells culled from a fertilized human egg that can grow into any type of cell in the body are a medical milestone seen only once every 100 years. Accordingly, Keirstead says, "I have never seen in my career a biological tool as powerful as the stem cell. It addresses every single human disease." (emphasis mine) That's a claim that, if proven true, has the power to create a pre- and post-stem cell world where everything you think about medicine is changed forever. And while the stem cell industry still has quite a bit of ground to cover to establish itself, the market for these new treatment options is expected to be worth $63.8 billion by 2015, or three times its current size. Even still, the FDA has been slow to approve new stem cell trials. To date, only Geron Corporation (NASDAQ: GERN) and Advanced Cell Technology (OTC: ACTC) have been given the green light to proceed with this vital new research. As I wrote about in an earlier article, Geron is working on a Phase I trial to cure spinal paralysis, while Advanced Cell Technology recently enrolled the first two patients in a trial using embryonic stem cells to treat macular degeneration, a common cause of vision loss. Even still, for scientists, prospective patients and investors alike are only in the early stages of what may one day be world changing developments. Advertisement Retire Healthy and Wealthy One company is the key to your long-lived and prosperous retirement. It's a small biotech that uses your own tissue to grow new organs and limbs. That's for your health. And it trades for $3.00 with the backing of some of the world's largest drug companies. That's for your wealth. The $50 Trillion Windfall Especially if they can figure out how to cure cancer.... Because prospective patients won't be the only winners when cancer gets shown the door. The economic impact will be off the charts. In fact, according to a study presented by the Chicago Graduate School of Business five years ago, a cure for cancer would have an economic value of $50 trillion for Americans alone — about four times the current size of U.S. GDP. Factor in the rest of the industrialized world, and that figure exceeds $100 trillion. Even small advancements would have a significant impact. According to the same study, a mere 1 percent reduction in mortality rates from cancer would be worth nearly $500 billion. Those figures, of course, are just the beginning of the advancements the biotech sector will one day usher in. That's why for the last two years I've been recommending the SPDR S&P Biotech ETF (NYSE: XBI). Since then, its up over 51%, with plenty more room to the upside. Another area where early biotech investors with a speculative bent can make a small fortune is in regenerative medicine. It's the new technology that promises to one day make organ donor lists a thing of the past. In fact, I've have found the one company whose scientists are creating living, functional tissue to repair or replace organ function lost to age, disease, or congenital defects. It is nothing less than science fiction brought to life. In fact, you can learn more about this cutting edge new company by clicking here. As you will see, to call what they do “revolutionary” doesn't do it justice. In the meantime, take solace in today's troubled markets with the knowledge the next big thing is always where we seem to find it – just around the bend. Your bargain-hunting analyst,   Steve Christ Editor, Wealth Daily Refer a Friend to Wealth Daily

Related Articles The Only Biotech Stock to Own for 2011 The Miracle of Regenerative Medicine 2011 ASCO Trades Wealth Daily Blogs Rare Earth Crisis Out of Hand Prices are still exploding... Muddy Waters Charged? Some one's not too happy... Shiller: "There has never been a bust of this proportion" The gift that keeps on giving.... Economic Releases for the week of Monday, June 20th, 2011: Jun 21 - Existing Home Sales Jun 24 - Durable Orders Jun 22 - MBA Mortgage Index Jun 22 - FOMC Rate Decision Jun 23 - New Home Sales Jun 24 - GDP You May Also Enjoy... Human Behavior Governs Exactly When the Coming Downturn Happens 2011-06-21 - Adam Lass Everybody's Got Problems, Profit from the Solutions 2011-06-20 - Christian A. DeHaemer Wealth Daily's Weekend Edition 2011-06-19 - Steve Christ Nickel Will Fall Victim to Oversupply 2011-06-17 - Luke Burgess What's Goldman Up to This Time? 2011-06-16 - Ian Cooper

You can manage your subscription and get our privacy policy here. Wealth Daily, Copyright © 2011, Angel Publishing LLC, P.O. Box 84905, Phoenix, AZ 85071. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Wealth Daily does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this newsletter. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription.